Research
Print page Print page
Switch language
Rigshospitalet - a part of Copenhagen University Hospital
Published

Long-term efficacy and safety of migalastat treatment in Fabry disease: 30-month results from the open-label extension of the randomized, phase 3 ATTRACT study

Research output: Contribution to journalJournal articleResearchpeer-review

  1. Approach to the patient with glucocorticoid-induced adrenal insufficiency

    Research output: Contribution to journalReviewResearchpeer-review

  2. Severe weight loss in a hypothyroid patient as an acute presentation of autoimmune polyglandular syndrome type II

    Research output: Contribution to journalReviewResearchpeer-review

  3. Randomized Controlled Trial of Tesomet for Weight Loss in Hypothalamic Obesity

    Research output: Contribution to journalJournal articleResearchpeer-review

  4. Thyroid Disease and Hepatocellular Carcinoma Survival: A Danish Nationwide Cohort Study

    Research output: Contribution to journalJournal articleResearchpeer-review

  • Ulla Feldt-Rasmussen
  • Derralynn Hughes
  • Gere Sunder-Plassmann
  • Suma Shankar
  • Khan Nedd
  • Iacopo Olivotto
  • Damara Ortiz
  • Toya Ohashi
  • Takashi Hamazaki
  • Nina Skuban
  • Julie Yu
  • Jay A Barth
  • Kathleen Nicholls
View graph of relations

Results from the 18-month randomized treatment period of the phase 3 ATTRACT study demonstrated the efficacy and safety of oral migalastat compared with enzyme replacement therapy (ERT) in patients with Fabry disease who previously received ERT. Here, we report data from the subsequent 12-month, migalastat-only, open-label extension (OLE) period. ATTRACT (Study AT1001-012; NCT01218659) was a randomized, open-label, active-controlled study in patients aged 16-74 years with Fabry disease, an amenable GLA variant, and an estimated glomerular filtration rate (eGFR) ≥30 mL/min/1.73 m2. During the OLE, patients who received migalastat 150 mg every other day (QOD) during the randomized period continued receiving migalastat (Group 1 [MM]); patients who received ERT every other week discontinued ERT and started migalastat treatment (Group 2 [EM]). Outcome measures included eGFR, left ventricular mass index (LVMi), composite clinical outcome (renal, cardiac or cerebrovascular events), and safety. Forty-six patients who completed the randomized treatment period continued into the OLE (Group 1 [MM], n = 31; Group 2 [EM], n = 15). eGFR remained stable in both treatment groups. LVMi decreased from baseline at month 30 in Group 1 (MM) in patients with left ventricular hypertrophy at baseline. Only 10% of patients experienced a new composite clinical event with migalastat treatment during the OLE. No new safety concerns were reported. In conclusion, in patients with Fabry disease and amenable GLA variants, migalastat 150 mg QOD was well tolerated and demonstrated durable, long-term stability of renal function and reduction in LVMi.

Original languageEnglish
JournalMolecular Genetics and Metabolism
Volume131
Issue number1-2
Pages (from-to)219-228
Number of pages10
ISSN1096-7192
DOIs
Publication statusPublished - 6 Oct 2020

ID: 61808067